# US 2016/0237075 A1 · Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237075 A1
- Document ID: US20160237075A1
- Status: Published application
- Kind: A1
- Application number: 15/025,654
- Filed: 2014-09-29
- Published: 2016-08-18
- Earliest claimed: 2013-09-30
- Assignees: Beijing Synercare Pharma Tech Co., Ltd.
- Applicants: Beijing Synercare Pharma Tech Co., Ltd.
- Inventors: Xiangyang CHEN; Yingxiang GAO; Chong LIU; Haihong NI; Mark MULVIHILL
- Web page: https://patentgrep.com/patent/US20160237075A1

## CPC

- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 213/82: in position 3
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 295/185: from aliphatic carboxylic acids
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

## Claims

### Claim 1

A compound according to Formula I:
wherein:
A is selected from C3-12cycloalkyl, C3-12heterocycloalkyl, C3-12aryl, or C3-12heteroaryl, any of which is optionally substituted with G1 substituents;
B1 is selected from C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G2 substituents;
B2 is selected from C0-12alkyl, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G3 substituents;
L1 is selected from —C0-2alkyl-, —CR5R6—, —C0-3alkyl(R5)(OH)—, —C(O)—, —CH2O—, —OCH2—, —CF2—, —SCR5R6—, —CR5R6S—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, —N(R5)C(O)N(R6)—, —O—, —S—, —S(O)m1—, —N(R5)S(O)m1—, or —S(O)m1N(R5)—;
L2 is selected from —C0-4alkyl-, —C(O)—, —N(R7)—, —N(R7)C(O)—, or —N(R7)S(O)m2—;
X is selected from C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G4 substituents;
Y is selected from —C(O)—, —N(R8)—, —N(R8)C(O)—, —S(O)m3—, or —N(R8)S(O)m3—;
R1 is selected from —C(O)R9, —C(O)NR9R10, —C(O)OR9, C1-4alkynyl, OR9, S(O)m4R9R10, or —CN;
R2, R3, and R4 are each independently selected from C0-12alkyl, —CN, halo, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G5 substituents;
R5, R6, R7, R8, R9, and R10 are each independently selected from C0-12alkyl, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G6 substituents;
G1, G2, G3, G4, G5, and G6 are each independently selected from one or more of C0-12alkyl, —C2-12alkenyl, —C2-12alkynyl, D, -CD3, —OCD3, halo, —CN, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —P(O)C0-3 alkyl, —PO(OR11)2, —PO(OR11)R12, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C0-6alkylOR11, —OC(O)NR11R12, —C(O)OR11, —C(O)NR11R12, —C(O)R11, —NR11R12, —NR11C(O)R12, —NR13C(O)NR11R12, —S(O)m5R11, and —NR11S(O)m5R12, any of which is optionally substituted with independently selected Q1 substituents;
Q1 is selected from one or more of C0-12alkyl-, —C2-12alkenyl, —C2-12alkynyl, D, halo, —CN, -CD3, —OCD3, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —PO(OR14)2, —PO(OR14)R15, NR14R15, —C(O)NR14OH, —C0-6alkylOR14, aryl-C0-12alkyl-, heteroaryl-C0-12alkyl-, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12cycloalkyl-, heteroaryl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12cycloalkyl-, C3-12cycloalkyl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12heterocycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C(O)—C(O)NR14R15, —C(O)—C(O)OR14, —OC(O)R14, —NR14C(O)R15, —NR14S(O)m6R15, —(CR15R16)n1C(O)R14, —(CR15R16)n1C(O)OR14, —(CR15R16)n1C(O)NR14R17, (CR15R16)n1S(O)m6NR14R17, —(CR15R16)n1NR14R17, —(CR15R16)n1OR14, —(CR15R16)n1S(O)m6R14, —NR16C(O)NR14R15, and —NR16S(O)m6NR14R15, any of which is optionally substituted with independently selected E1 substituents;
E1 is selected from one or more of C0-12alkyl-, —C2-12alkenyl, —C2-12alkynyl, D, halo, —CN, -oxo-, -CD3, —OCD3, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —PO(OR18)2, —PO(OR18)R19, —C(O)NR18OH, —C(O)NR18R19, —C0-12alkylOR18, aryl-C0-12alkyl-, heteroaryl-C0-12alkyl-, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12cycloalkyl-, heteroaryl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12cycloalkyl-, C3-12cycloalkyl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12heterocycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C(O)—C(O)NR18R19, —C0-12alkylC(O)OR18, —C(O)—C(O)OR18, —OC(O)R18, —NR18C(O)R19, —NR18C(O)OR19, —NR18S(O)m7R19, —(CR19R20)n2C(O)R18, —(CR19R20)n2C(O)OR18, —(CR19R20)n2C(O)NR18R21, —(CR19R20)n2S(O)m7NR18R21, —(CR19R20)n2NR18R21, —(CR19R20)n2OR18, —(CR19R20)n2S(O)m7R18, —NR20C(O)NR18R19, and —NR20S(O)m7NR18R19 substituents;
R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, and R21 are each independently selected from H, C1-6alkyl-, C3-8cycloalkyl-C0-6alkyl-, C3-8heterocycloalkyl-C0-6alkyl-, aryl-C0-6alkyl-, aryl-C3-8cycloalkyl-, aryl-C3-8heterocycloalkyl-, heteroaryl-C1-6alkyl-, heteroaryl-C3-8cycloalkyl-, or heteroaryl-C3-8heterocycloalkyl-;
R3 and R4 are taken together with the carbon atoms to which they are attached to form a 3-12 membered partially saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m8;
m1, m2, m3, m4, m5, m6, m7, m8, n1, and n2 are each independently selected from 0, 1, or 2;
or a pharmaceutically acceptable salt, solvate or a prodrug thereof.

### Claim 2 (depends on 1)

The compound or salt of claim 1, which is represented by Formula Ia:
wherein:
B1 is selected from C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G2 substituents;
B2 is selected from C0-12alkyl, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G3 substituents;
L1 is selected from —C0-12alkyl-, —CR5R6—, —C0-3alkyl(R5)(OH)—, —C(O)—, —CH2O—, —OCH2—, —CF2—, —SCR5R6—, —CR5R6S—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, —N(R5)C(O)N(R6)—, —O—, —S—, —S(O)m1—, —N(R5)S(O)m1—, or —S(O)m1N(R5)—;
L2 is selected from —C0-4alkyl-, —C(O)—, —N(R7)—, —N(R7)C(O)—, or N(R7)S(O)m2—;
X is selected from C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G4 substituents;
Y is selected from —C(O)—, —N(R8)—, —N(R8)C(O)—, —S(O)m3—, or —N(R8)S(O)m3—;
Z1 is (CRa)0-1;
Z2 is selected from CRb, NRb, O, or S;
Z3 is selected from C or N;
Z4 is selected from CRc, NRc, O, or S;
R1 is selected from —C(O)R9, —C(O)NR9R10, —C(O)OR9, C1-4alkynyl, OR9, S(O)m4R9R10, or —CN;
R2, R3, R4, Ra, Rb, and R are each independently selected from C0-12alkyl, —CN, halo, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G5 substituents;
R5, R6, R7, R8, R9, and R10 are each independently selected from C0-12alkyl, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G6 substituents;
G1, G2, G3, G4, G5, and G6 are each independently selected from one or more of C0-12alkyl, —C2-12alkenyl, —C2-12alkynyl, D, -CD3, —OCD3, halo, —CN, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —P(O)C0-3 alkyl, —PO(OR11)2, —PO(OR11)R12, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C0-6alkylOR11, —OC(O)NR11R12, —C(O)OR11, —C(O)NR11R12, —C(O)R11, —NR11R12, —NR11C(O)R12, —NR13C(O)NR11R12, —S(O)m5R11, and —NR11S(O)m5R12, any of which is optionally substituted with independently selected Q1 substituents;
Q1 is selected from one or more of C0-12alkyl-, —C2-12alkenyl, —C2-12alkynyl, D, halo, —CN, -CD3, —OCD3, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —PO(OR14)2, —PO(OR14)R15, NR14R15, —C(O)NR14OH, —C0-6alkylOR14, C0-12alkyl-, aryl-C0-12alkyl-, heteroaryl-C0-12alkyl-, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12cycloalkyl-, heteroaryl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12cycloalkyl-, C3-12cycloalkyl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12heterocycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C(O)—C(O)NR14R15, —C(O)—C(O)OR14, —OC(O)R14, —NR14C(O)R11, —NR14S(O)m6R15, —(CR15R16)n1C(O)R14, —(CR15R16)n1C(O)OR14, —(CR15R16)n1C(O)NR14R17, —(CR15R16)n1S(O)m6NR14R17, —(CR15R16)n1NR14R17, —(CR15R16)n1OR14, —(CR15R16)n1S(O)m6R14, —NR16C(O)NR14R15, and —NR16S(O)m6NR14R15, any of which is optionally substituted with independently selected E1 substituents;
E1 is selected from one or more of C0-12alkyl-, —C2-12alkenyl, —C2-12alkynyl, D, halo, —CN, -oxo-, -CD3, —OCD3, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —PO(OR18)2, —PO(OR18)R19, —C(O)NR18OH, —C(O)NR18R19, —C0-12alkylOR18, aryl-C0-12alkyl-, heteroaryl-C0-12alkyl-, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12cycloalkyl-, heteroaryl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12cycloalkyl-, C3-12cycloalkyl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12heterocycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C(O)—C(O)NR18R19, —C0-12alkylC(O)OR18, —C(O)—C(O)OR18, —OC(O)R18, —NR18C(O)R19, —NR18C(O)OR19, —NR18S(O)m7R19, —(CR19R20)n2C(O)R18, —(CR19R20)n2C(O)OR18, —(CR19R20)n2C(O)NR18R21, —(CR19R20)n2S(O)m7NR19R21, —(CR19R20)n2NR18R21, —(CR19R20)n2OR18, —(CR19R20)n2S(O)m7R18, —NR20C(O)NR18R19, and —NR20S(O)m7NR18R19 substituents;
R11, R12, R13, R14, R15, R16, R18, R19, R20, and R21 are each independently selected from H, C1-6alkyl-, C3-8cycloalkyl-C0-6alkyl-, C3-8heterocycloalkyl-C0-6alkyl-, aryl-C0-6alkyl-, aryl-C3-8cycloalkyl-, aryl-C3-8heterocycloalkyl-, heteroaryl-C1-6alkyl-, heteroaryl-C3-8cycloalkyl-, or heteroaryl-C3-8heterocycloalkyl-;
R3 and R4 are taken together with the carbon atoms to which they are attached to form a 3-12 membered partially saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m8;
m1, m2, m3, m4, m5, m6, m7, m8, n1, and n2 are each independently selected from 0, 1, or 2;
or a pharmaceutically acceptable salt, solvate or a prodrug thereof.

### Claim 3 (depends on 1)

The compound or salt of claim 1, wherein the compound of Formula I is selected from one of Formulas Ib-Ii:
wherein:
B1 is selected from C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G2 substituents;
B2 is selected from C0-12alkyl, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G3 substituents;
L1 is selected from —C0-12alkyl-, —CR5R6—, —C0-3alkyl(R5)(OH)—, —C(O)—, —CH2O—, —OCH2—, —CF2—, —SCR5R6—, —CR5R6S—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, —N(R5)C(O)N(R6)—, —O—, —S—, —S(O)m1—, —N(R5)S(O)m1—, or —S(O)m1N(R5)—;
L2 is selected from —C0-4alkyl-, —C(O)—, —N(R7)—, —N(R7)C(O)—, or —N(R7)S(O)m2—;
X is selected from C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G4 substituents;
Y is selected from —C(O)—, —N(R8)—, —N(R8)C(O)—, —S(O)m3—, or —N(R8)S(O)m3—;
R1 is selected from —C(O)R9, —C(O)NR9R10, —C(O)OR9, C1-4alkynyl, OR9, S(O)m4R9R10, or —CN;
R2, R3, and R4 are each independently selected from C0-12alkyl, —CN, halo, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G5 substituents;
R5, R6, R7, R8, R9, and R10 are each independently selected from C0-12alkyl, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G6 substituents;
G1, G2, G3, G4, G5, and G6 are each independently selected from one or more of C0-12alkyl, —C2-12alkenyl, —C2-12alkynyl, D, -CD3, —OCD3, halo, —CN, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —P(O)C0-3 alkyl, —PO(OR11)2, —PO(OR11)R12, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C0-6alkylOR11, —OC(O)NR11R12, —C(O)OR11, —C(O)NR11R12, —C(O)R11, —NR11R12, —NR11C(O)R12, —NR13C(O)NR11R12, —S(O)m5R11, and —NR11S(O)m5R12, any of which is optionally substituted with independently selected Q1 substituents;
Q1 is selected from one or more of C0-12alkyl-, —C2-12alkenyl, —C2-12alkynyl, D, halo, —CN, -CD3, —OCD3, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —PO(OR14)2, —PO(OR14)R15, NR14R15, —C(O)NR14OH, —C0-6alkylOR14, aryl-C0-12alkyl-, heteroaryl-C0-12alkyl-, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12cycloalkyl-, heteroaryl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12cycloalkyl-, C3-12cycloalkyl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12heterocycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C(O)—C(O)NR14R15, —C(O)—C(O)OR14, —OC(O)R14, —NR14C(O)R15, —NR14S(O)m6R15, —(CR15R16)n1C(O)R14, —(CR15R16)n1C(O)OR14, —(CR15R16)n1C(O)NR14R17, —(CR15R16)n1S(O)m6NR14R17, —(CR15R16)n1NR14R17, —(CR15R16)n1OR14, —(CR15R16)n1S(O)m6R14, —NR16C(O)NR14R15, and —NR16S(O)m6NR14R15, any of which is optionally substituted with independently selected E1 substituents;
E1 is selected from one or more of C0-12alkyl-, —C2-12alkenyl, —C2-12alkynyl, D, halo, —CN, -oxo-, -CD3, —OCD3, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —PO(OR18)2, —PO(OR18)R19, —C(O)NR1OH, —C(O)NR18R19, —C0-12alkylOR18, aryl-C0-12alkyl-, heteroaryl-C0-12alkyl-, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12cycloalkyl-, heteroaryl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12cycloalkyl-, C3-12cycloalkyl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12heterocycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C(O)—C(O)NR18R19, —C0-12alkylC(O)OR18, —C(O)—C(O)OR18, —OC(O)R18, —NR18C(O)R19, —NR18C(O)OR19, —NR18S(O)m7R19, —(CR19R20)n2C(O)R18, —(CR19R20)n2C(O)OR18, —(CR19R20)n2C(O)NR18R21, —(CR19R20)n2S(O)m7NR18R21, —(CR19R20)n2NR18R21, —(CR19R20)n2OR18, —(CR19R20)n2S(O)m7R18, —NR20C(O)NR18R19, and —NR20S(O)m7NR18R19 substituents;
R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, and R21 are each independently selected from H, C1-6alkyl-, C3-8cycloalkyl-C0-6alkyl-, C3-8heterocycloalkyl-C0-6alkyl-, aryl-C0-6alkyl-, aryl-C3-8cycloalkyl-, aryl-C3-8heterocycloalkyl-, heteroaryl-C1-6alkyl-, heteroaryl-C3-8cycloalkyl-, or heteroaryl-C3-8heterocycloalkyl-;
R3 and R4 are taken together with the carbon atoms to which they are attached to form a 3-12 membered partially saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m8;
m1, m2, m3, m4, m5, m6, m7, m8, n1, and n2 are each independently selected from 0, 1, or 2;
or a pharmaceutically acceptable salt, solvate or a prodrug thereof.

### Claim 4 (depends on 1)

The compound or salt of claim 1, wherein B1 is selected from C4-8cycloalkyl-C0-12alkyl-, C4-8heterocycloalkyl-C0-12alkyl-, C4-8aryl-C0-12alkyl-, or C4-8heteroaryl-C0-12alkyl-, any of which is optionally substituted with G2 substituents.

### Claim 5 (depends on 1)

The compound or salt of claim 1, wherein B2 is selected from C4-8cycloalkyl-C0-12alkyl-, C4-8heterocycloalkyl-C0-12alkyl-, C4-8aryl-C0-12alkyl-, or C4-8heteroaryl-C0-12alkyl-, any of which is optionally substituted with G3 substituents.

### Claim 6 (depends on 1)

The compound or salt of claim 1, wherein L1 is selected from —C0-2alkyl-, —CR5R6—, —C0-3alkyl(R5)(OH)—, —C(O)—, —CH2O—, —OCH2—, —CF2—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, —O—, or —S(O)m1—.

### Claim 7 (depends on 1)

The compound or salt of claim 1, wherein L1 is selected from —C0-2alkyl-, —CR5R6—, —C1-2alkyl(R5)(OH)—, —C(O)—, —CF2—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, —O—, or —S(O)m1—.

### Claim 8 (depends on 1)

The compound or salt of claim 1, wherein L2 is selected from —C0-2alkyl-, —C(O)—, or —N(R7)—.

### Claim 9 (depends on 1)

The compound or salt of claim 1, wherein X is selected from C4-8cycloalkyl-C0-12alkyl-, C4-8heterocycloalkyl-C0-12alkyl-, C4-8aryl-C0-12alkyl-, or C4-8heteroaryl-C0-12alkyl-.

### Claim 10 (depends on 1)

The compound or salt of claim 1, wherein Y is selected from —C(O)—, —N(R8)—, —N(R8)C(O)—, or —S(O)m3—.

### Claim 11 (depends on 1)

The compound or salt of claim 1, wherein R1 is selected from —C(O)NR9R10, —C(O)OR9, C1-4alkynyl, or —CN.

### Claim 12 (depends on 1)

The compound or salt of claim 1, wherein R2, R3, and R4 are each independently selected from C0-12alkyl, —CN, halo, C3-6cycloalkyl-C0-12alkyl-, or C3-6heterocycloalkyl-C0-12alkyl-, any of which is optionally substituted with G5 substituents.

### Claim 13 (depends on 1)

The compound or salt of claim 1, wherein G1, G2, G3, G4, G5, and G6 are each independently selected from one to three of C0-12alkyl, —C2-12alkenyl, —C2-12alkynyl, D, -CD3, —OCD3, halo, —CN, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —P(O)C0-3 alkyl, —PO(OR11)2, —PO(OR11)R12, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C0-6alkylOR11, —OC(O)NR11R12, —C(O)OR11, —C(O)NR11R12, —C(O)R11, —NR11R12, —NR11C(O)R12, —NR13C(O)NR11R12, —S(O)m5R11, and —NR11S(O)m5R12, any of which is optionally substituted with independently selected Q1 substituents.

### Claim 14 (depends on 1)

The compound or salt of claim 1, wherein G1, G2, G3, G4, G5, and G6 are each independently selected from one to two of C0-12alkyl, —C2-12alkenyl, —C2-12alkynyl, D, -CD3, —OCD3, halo, —CN, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —P(O)C0-3alkyl, —PO(OR11)2, —PO(OR11)R12, C3-12cycloalkyl-C12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C0-6alkylOR11, —OC(O)NR11R12, —C(O)OR11, —C(O)NR11R12, —C(O)R11, —NR11R12, —NR11C(O)R12, —NR13C(O)NR11R12, —S(O)m5R11, and —NR11S(O)m5R12, any of which is optionally substituted with independently selected Q substituents.

### Claim 15

A pharmaceutical composition comprising the compound or salt of any one of the compounds of Formula I, formulated with or without one or more pharmaceutical carriers.

### Claim 16

A method for the treatment of at least one of cancer, chronic inflammation, and autoimmune disease mediated at least in part by BTK comprising administering to a subject in need thereof a therapeutically effective amount of a compound or salt of the compound of Formula I.

### Claim 17 (depends on 1)

A method of treating cancer, chronic inflammation, or autoimmune disease in a mammal comprising administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to the mammal in need thereof.

### Claim 18 (depends on 1)

A method of irreversibly inhibiting tyrosine kinases, the method comprising administering to a patient a therapeutically effective amount of a tyrosine kinase inhibitor comprising a compound according to claim 1.

### Claim 19 (depends on 1)

A method of irreversibly inhibiting BTK, the method comprising administering to a patient a therapeutically effective amount of a BTK inhibitor comprising a compound according to claim 1.

### Claim 20

A compound selected from one or more of:
6-(3-acrylamidophenyl)-2-(4-phenoxyphenyl)nicotinamide;
2-(4-phenoxyphenyl)-6-(piperidin-4-yl)nicotinamide;
6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide;
2-(4-phenoxyphenyl)-6-(piperazin-1-yl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-phenoxyphenyl)nicotinamide;
6-(1-acryloylpyrrolidin-3-yl)-2-(4-phenoxyphenyl)nicotinamide;
6-(4-acrylamidophenyl)-2-(4-phenoxyphenyl)nicotinamide;
6-(1-acryloylpiperidin-3-yl)-2-(4-phenoxyphenyl)nicotinamide;
6-(4-acrylamidopiperidin-1-yl)-2-(4-phenoxyphenyl)nicotinamide;
6-(3-acrylamidopyrrolidin-1-yl)-2-(4-phenoxyphenyl)nicotinamide;
1-(1-acryloylpiperidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
1-(1-acryloylpiperidin-4-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
1-(1-acryloylpyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
1-(azetidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
1-(1-acryloylazetidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
1-(4-acrylamidophenyl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
1-(3-aminophenyl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
1-(3-acrylamidophenyl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
(S)-1-(1-acryloylpyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
(R)-1-(1-acryloylpyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
2-(1-acryloylpiperidin-4-yl)-4-(4-phenoxyphenyl)pyrimidine-5-carboxamide;
2-(1-acryloylpyrrolidin-3-yl)-4-(4-phenoxyphenyl)pyrimidine-5-carboxamide;
6-(1-acryloylpyrrolidin-3-yl)-2-(4-phenoxyphenyl)pyridine-3-carboxamide;
6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)pyridine-3-carbonitrile
(E)-6-(4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)-2-(4-phenoxyphenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-phenoxyphenyl)pyridine-3-carboxylic acid
6-(4-acryloylpiperazin-1-yl)-2-(4-(4-cyanophenoxy)phenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-(0)phenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(3-methoxy-4-methylphenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-fluoro-3-methoxyphenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-6′-phenoxy-2,3′-bipyridine-3-carboxamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-(pyridin-2-yloxy)phenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-chlorophenyl)nicotinamide;
1-(1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-(3-fluorophenoxy)phenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(3-fluoro-4-phenoxyphenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-(4-fluorophenoxy)phenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-(2-fluorophenoxy)phenyl)nicotinamide;
6-(4-acryloylpiperazin-1-yl)-2-(2-fluoro-4-phenoxyphenyl)nicotinamide;
2-(1-acryloylpiperidin-3-yl)-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
2-(1-acryloylpyrrolidin-3-yl)-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
2-(1-acryloylpiperidin-3-yl)-4-(4-phenoxyphenyl)oxazole-5-carboxamide;
2-(1-acryloylpyrrolidin-3-yl)-4-(4-phenoxyphenyl)oxazole-5-carboxamide;
2-(1-acryloylpyrrolidin-3-yl)-5-(4-phenoxyphenyl)thiazole-4-carboxamide;
2-(1-acryloylpiperidin-3-yl)-5-(4-phenoxyphenyl)thiazole-4-carboxamide;
2-(1-acryloylpiperidin-4-yl)-4-(4-phenoxyphenyl)oxazole-5-carboxamide;
2-(4-acryloylpiperazin-1-yl)-N-methyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
2-(1-acryloylpyrrolidin-3-yl)-5-(4-phenoxyphenyl)oxazole-4-carboxamide;
2-(1-acryloylpiperidin-4-yl)-5-(4-phenoxyphenyl)thiazole-4-carboxamide;
2-(4-acryloylpiperazin-1-yl)-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
2-(1-acryloylpiperidin-4-yl)-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
(E)-1-(1-(2-cyano-3-cyclopropylacryloyl)azetidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
1-cyclopentyl-5-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
2-(1-acryloylpiperidin-3-yl)-5-(4-phenoxyphenyl)oxazole-4-carboxamide;
5-(1-acryloylpiperidin-4-yl)-4′-phenoxybiphenyl-2-carboxamide;
5-(1-acryloylpiperidin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrazole-3-carboxamide;
5-(4-acryloylpiperazin-1-yl)-4′-phenoxybiphenyl-2-carboxamide;
6-(1-acryloylpiperidin-4-yl)-2-(4-(hydroxy(phenyl)methyl)phenyl)nicotinamide;
(E)-1-(1-(2-cyanobut-2-enoyl)azetidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
6-(4-acryloylpiperazin-1-yl)-2-(4-((4,4-difluorocyclohexyl)oxy)phenyl)nicotinamide;
6-(1-acryloylpiperidin-4-yl)-2-(4-(phenylcarbamoyl)phenyl)nicotinamide;
6-cyclohexyl-2-(4-phenoxyphenyl)nicotinamide;
2-(4-phenoxyphenyl)-6-(4-(vinylsulfonyl)piperazin-1-yl)nicotinamide;
2-(4-phenoxyphenyl)-6-(1-(vinylsulfonyl)piperidin-4-yl)nicotinamide;
1-(1-acryloylpiperidin-3-yl)-3-(4-(phenylcarbamoyl)phenyl)-1H-pyrazole-4-carboxamide;
1-(1-acryloylpiperidin-3-yl)-3-(4-((4-(trifluoromethyl)pyridin-2-yl)carbamoyl)phenyl)-1H-pyrazole-4-carboxamide;
6-(4-acrylamidophenyl)-2-(4-(phenylcarbamoyl)phenyl) nicotinamide;
6-(4-acrylamidophenyl)-2-(4-((4-(trifluoromethyl)pyridin-2-yl)carbamoyl)phenyl) nicotinamide;
1-(1-acryloylpiperidin-3-yl)-3-(4-(hydroxy(phenyl)methyl)phenyl)-1H-pyrazole-4-carboxamide;
1-(1-acryloylpiperidin-3-yl)-3-(4-(methyl(phenyl)amino)phenyl)-1H-pyrazole-4-carboxamide;
6-(4-acrylamidophenyl)-2-(4-(1-hydroxy-1-phenylethyl)phenyl)nicotinamide;
6-(4-acrylamidophenyl)-2-(4-(difluoro(phenyl)methyl)phenyl)nicotinamide;
1-(1-acryloylpiperidin-3-yl)-3-(4-(phenylsulfonyl)phenyl)-1H-pyrazole-4-carboxamide;
6-(4-acrylamidophenyl)-2-(4-(phenylsulfonyl)phenyl) nicotinamide;
or a pharmaceutically acceptable salt thereof.
